North America Heart Pump Device Market Size & Forecast 2025–2033

According to Renub Research Latest Report North America Heart Pump Device Market is projected to grow from US$ 2.92 billion in 2024 to US$ 8.1 billion by 2033, registering a robust CAGR of 12% between 2025 and 2033. This surge is primarily fueled by technological advancements in heart pump devices, rising prevalence of cardiovascular diseases, and the growing geriatric population in the region. With innovation in ventricular assist devices (VADs), intra-aortic balloon pumps (IABPs), and fully implantable heart pumps, coupled with strong healthcare infrastructure and reimbursement policies, North America remains the global leader in heart pump adoption.

Market Overview

Heart pump devices are mechanical systems designed to aid or replace the pumping function of the heart, primarily for patients with advanced heart failure or severe cardiovascular disease. These devices—including left ventricular assist devices (LVADs), total artificial hearts (TAHs), and intra-aortic balloon pumps—improve blood circulation, relieve heart failure symptoms, and maintain patient quality of life. They are crucial for bridge-to-transplant therapies, patients ineligible for transplant, or those recovering from heart attacks or high-risk surgeries.

The rising incidence of heart disease in North America, driven by sedentary lifestyles, obesity, hypertension, and diabetes, has increased demand for life-supporting cardiac devices. At the same time, technological advancements in device design and functionality are making these systems safer, smaller, and more efficient, allowing broader clinical application.

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Free Sample Report

Growth Drivers

1. Rising Prevalence of Cardiovascular Diseases

North America has one of the highest burdens of cardiovascular diseases (CVDs) globally. According to 2023 data, 919,032 Americans succumbed to CVDs, representing 1 in every 3 deaths. With an aging population—particularly in Canada, where seniors (65+) are expected to reach 21.6–29.8% by 2068—the need for advanced heart therapies is intensifying. Conditions such as heart failure, coronary artery disease, and arrhythmia are key contributors to rising device adoption. Lifestyle-related comorbidities, including diabetes, obesity, and hypertension, further drive demand for ventricular assist devices, intra-aortic balloon pumps, and implanted heart pumps.

2. Technological Innovation in Heart Pump Devices

Innovation is central to market growth. Key advancements include:

Miniaturized devices that reduce surgical trauma and enhance patient comfort.

Fully implantable LVADs with wireless power and remote monitoring capabilities.

Improved biocompatibility, minimizing thrombosis, infection, and device rejection.

Intelligent features like smart sensors for early detection of complications.

For instance, in December 2024, the FDA approved expanded use of Johnson & Johnson MedTech’s Impella 5.5 with SmartAssist and Impella CP with SmartAssist for pediatric patients with acute decompensated heart failure and cardiogenic shock, highlighting continuous innovation in device indications.

3. Supportive Reimbursement and Healthcare Infrastructure

Robust healthcare infrastructure and reimbursement policies in North America support device adoption. In the U.S., Medicare, Medicaid, and private insurers cover a wide array of cardiac interventions, reducing out-of-pocket costs. Canada’s single-payer system ensures equitable access to sophisticated therapies. Government programs, specialized cardiac centers, and ongoing medical professional training foster a conducive environment for ventricular assist device (VAD) and intra-aortic balloon pump (IABP) uptake.

Challenges

1. High Cost of Devices and Surgery

The high cost of devices and associated procedures remains a major challenge. A single VAD can cost tens of thousands of dollars, excluding hospitalization and follow-up care. While reimbursement mitigates some burden, out-of-pocket costs can be prohibitive, especially for lower-income patients. Hospital procurement and maintenance also create financial strain, occasionally limiting device availability.

2. Device-Related Risks and Complications

Despite technological improvements, heart pump devices carry risks such as blood clots, stroke, bleeding, and infections. Long-term dependence on devices may require replacement surgeries, adding clinical and economic burdens. Doctors may hesitate to recommend these devices for moderate heart failure due to safety concerns. Continuous monitoring and adherence to medical regimens are essential, which can be inconvenient for patients. These factors restrict wider adoption across some patient segments.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Market Segmentation

By Product

Ventricular Assist Devices (VADs)

Intra-Aortic Balloon Pumps (IABPs)

Extracorporeal Membrane Oxygenation (ECMO)

Total Artificial Hearts (TAHs)

By Type

Implanted Heart Pump Devices

Extracorporeal Heart Pump Devices

By End Use

Hospitals

Cardiac Centers

Research Institutes

By Region

United States

Canada

Segment Analysis

Ventricular Assist Devices (VADs)

VADs are the largest and fastest-growing segment, driven by end-stage heart failure cases. They serve as bridge-to-transplant, destination therapy, or bridge-to-recovery devices, providing life-critical support. Technological enhancements—smaller size, improved durability, wireless energy transfer, and reduced complication rates—are expanding their clinical integration. U.S. reimbursement policies and Canada’s public healthcare system further support adoption.

Intra-Aortic Balloon Pumps (IABPs)

IABPs are commonly used in acute myocardial infarction or cardiogenic shock, offering short-term circulatory support. Their less invasive design and affordability make them essential in emergency care, often bridging patients to VADs or transplants. Despite competition from newer percutaneous pumps, IABPs remain relevant due to ease of use and proven clinical outcomes.

Implanted Heart Pump Devices

Implanted devices, especially implantable VADs, are increasingly preferred for chronic heart failure management. They improve survival rates and quality of life, especially for patients ineligible for transplant. Innovations such as wireless charging, enhanced biocompatibility, and reduced device size are driving adoption in North American hospitals and specialty cardiac centers.

Hospitals and Cardiac Centers

Hospitals: Serve as primary adoption points due to specialized surgical teams, advanced operating rooms, and ICU availability. U.S. hospitals benefit from tertiary care infrastructure and reimbursement support, while Canadian hospitals leverage public funding for access equity.

Cardiac Centers: Specialized facilities provide advanced care, personalized treatment, and access to investigational devices via clinical trials. Their growing prevalence increases device adoption rates, particularly in the U.S., with Canada gradually expanding its specialized centers.

Regional Insights

United States

The U.S. dominates the North American heart pump market due to:

Sophisticated healthcare infrastructure

High cardiovascular disease prevalence

Strong reimbursement policies

Presence of leading medical device manufacturers

Ongoing clinical trials and FDA approvals for second-generation devices continue to expand treatment options. For example, in January 2025, surgeons at the University of Michigan implanted a novel mechanical heart pump in a clinical trial for end-stage heart failure patients, showcasing the U.S. commitment to innovation.

Canada

Canada’s market growth is steady due to:

Universal healthcare access, ensuring patients receive advanced cardiac therapies.

Increasing heart failure incidence driven by aging and lifestyle-related risk factors.

Use of VADs and IABPs in specialty cardiac centers.

In August 2024, Abbott received FDA approval for a label update for its HeartMate 3 LVAD, improving clinical outcomes, which also reflects in Canadian adoption.

Key Players

Major companies active in the North America heart pump device market include:

Abbott Inc.

Getinge AB

Teleflex Incorporated

Fresenius SE & Co. KGaA

LivaNova PLC

CorWave SA

JARVIK HEART, INC.

ABIOMED

These players focus on technological innovation, clinical trials, biocompatibility, and post-market support, ensuring high adoption in hospitals and specialized cardiac centers.

Conclusion

The North America Heart Pump Device Market is poised for sustained growth due to the increasing prevalence of cardiovascular diseases, aging demographics, and technological innovation in life-sustaining cardiac devices. While high device costs and procedural risks pose challenges, strong healthcare infrastructure, reimbursement support, and continuous R&D facilitate broader adoption.

Segments such as VADs, IABPs, and implanted heart pumps will continue to dominate, supported by hospitals, specialized cardiac centers, and research institutes. The U.S. leads the regional market, driven by clinical innovation, reimbursement frameworks, and research capabilities, while Canada maintains steady growth through publicly funded healthcare and equitable access.

As miniaturization, remote monitoring, and smart technologies evolve, North America will remain at the forefront of advanced cardiac care, enhancing patient outcomes and quality of life for those with advanced heart failure. The market is expected to achieve US$ 8.1 billion by 2033, cementing its position as a critical segment of the global cardiovascular device landscape.

Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.